Adverse events mentions rare in social media, says study

Share this article:
A study of 224 pharmaceutical brands across several social media sites found that less than 1% of posts mentioned adverse events.

The study, by Bellevue, WA-based social media monitoring shop Visible Technologies, found that a mere .3% of the 257,000 posts mentioning those pharma brands over a 30-day period included adverse events reports. Fewer still met the federal reporting requirements for adverse events reports, as most posters remained anonymous and did not provide contact details. Just 14% of those posts mentioning adverse events would have triggered reporting requirements for pharma marketers, including an identifiable name and contact method.

“These findings prove that AER reporting is far less common than people think, creating a safer harbor for pharmaceutical marketers who want to embrace the many opportunities that social media offers to engage with customers and build brand loyalty,” said Visible Technologies' regional director Greg Singh.

Concerns about adverse events reporting requirements have hindered pharma company participation in social media – most recently, by prompting many pharmas to flee Facebook when the company required them to allow comments on their pages.
Share this article:

Email Newsletters

More in News

BMS Q2 sales slip, Eliquis, Yervoy soar

BMS Q2 sales slip, Eliquis, Yervoy soar

The company attributed part of the Eliquis boost to the BMS-Pfizer DTC and education efforts.

Gilead, Merck HCV marketing battle may be on horizon

Gilead, Merck HCV marketing battle may be on ...

Disclosed in its earnings report yesterday, Gilead may have a card up its sleeve to counter Merck's experimental hep. C combo regimen.

Sales of Biogen MS pill pick up overseas

Sales of Biogen MS pill pick up overseas

Biogen Idec is seeing strong sales for blockbuster MS drug Tecfidera, especially overseas where it's beginning to catch fire this summer.